phase ib trial of r-chop plus iberdomide or golcadomide in aggressive b-cell lymphoma
Published 1 year ago • 105 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:42
final analysis of the ro-chop trial: romidepsin plus chop vs chop in previously untreated ptcl
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
2:43
first report of phase 3 robust trial: r2-chop for frontline dlbcl
-
21:38
drawing the line: the rationale behind blood tube collection order
-
4:37
alpha solutions at home - capillary blood collection kit
-
1:06:04
itp: novel treatments
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:27
the epoch-r clinical trial in burkitt lymphoma
-
1:23
findings from the ro-chop trial in patients with r/r ptcl
-
2:55
ibrutinib in combination with r-chop in dlbcl: does age make a difference?
-
2:42
subcutaneous epcoritamab in r/r b-cell nhl
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
4:15
phase ib trial of avid200 in refractory myelofibrosis
-
1:23
phoenix: ibrutinib in combination with r-chop for dlbcl
-
2:22
epcore cll-1: phase i trial of epcoritamab in r/r cll
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies